Ispire Technology (ISPR) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
8 May, 2026Executive summary
Revenue for Q3 FY2026 was $18.7M, down 28.7% year-over-year and sequentially, reflecting stabilization after strategic repositioning and improved operating discipline.
Net loss for the quarter was $9.5M ($0.17/share), improved from $10.9M year-over-year but higher than the prior quarter.
Cash increased by $468K sequentially to $18M, with improved financial control and working capital at $0.9M as of March 31, 2026.
Malaysia manufacturing platform launched, providing a 25% tariff advantage and regulatory exclusivity as the only licensed nicotine vapor manufacturer in the country.
Transition phase completed; now executing a phased growth roadmap with catalysts in large markets and a focus on profitability and cash flow positive in the second half of 2026.
Financial highlights
Revenue for the quarter was $18.7M, and for the nine months ended March 31, 2026, $69.3M, both down year-over-year.
Gross profit for the quarter was $2.0M (10.7% margin), impacted by $2.2M in one-time product returns from legacy cannabis customers.
Operating expenses (excluding credit loss/bad debt) were $5.9M, down 36% year-over-year and 3.7% sequentially.
Net loss for the nine months was $19.4M, improved from $24.5M in the prior year.
Net cash used in operating activities for the quarter was $319K, a significant improvement from the prior year.
Outlook and guidance
Targeting cash flow positive in the second half of 2026, with management also projecting positive cash flow in early fiscal 2027.
Q3 expected to be the low point for both top and bottom line, with an upward trajectory anticipated.
Revenue growth expected from Malaysian manufacturing and new revenue catalysts, with continued cost reductions.
Latest events from Ispire Technology
- Revenue fell 51.5% but cost controls and innovation position for future growth.ISPR
Q2 202612 Apr 2026 - FY2025 revenue hit $127.5M, fueled by tech innovation and global expansion.ISPR
Investor presentation13 Feb 2026 - Record revenue and margin gains, but net loss widened; global nicotine growth drives FY2025 outlook.ISPR
Q4 202420 Jan 2026 - Gross margin rose to 19.5% as profit improved, but revenue fell and losses widened.ISPR
Q1 202515 Jan 2026 - Shelf registration allows up to $120M in securities to fund growth and innovation in vaping markets.ISPR
Registration Filing16 Dec 2025 - Shareholders will vote on director elections, auditor ratification, and key governance matters.ISPR
Proxy Filing2 Dec 2025 - Gross margin rose to 18.5% on flat revenue, but net loss widened amid global expansion.ISPR
Q2 20251 Dec 2025 - Q3 revenue dropped 12.7% to $26.2M as losses widened and Malaysia shift aims to cut costs.ISPR
Q3 202526 Nov 2025 - Revenue down 22.8% to $30.4M, net loss narrows, and cost controls improve EBITDA.ISPR
Q1 202613 Nov 2025